Zentalis Pharmaceuticals

Historical price data

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering and developing differentiated small molecule therapeutics for cancer. Its primary achievement is the advancement of azenosertib, a potentially best-in-class WEE1 inhibitor, which has secured FDA Fast Track designation for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The company's strategy is biomarker-driven, focusing initially on this high-need PROC population while exploring broader combination potential across multiple tumor types to maximize the asset's franchise value.

Focused on the discovery and development of selective small molecule kinase inhibitors, with core expertise in WEE1 inhibition and a biomarker-driven development strategy for cancers with replication stress.

The WEE1 inhibitor space is open after AstraZeneca's deprioritization of adavosertib. Azenosertib's primary competition comes from other DNA damage response agents (PARP inhibitors, ADCs) in ovarian cancer, but it targets a distinct, biomarker-defined population. Its claimed selectivity profile is its key potential differentiator.